Sign in
Active, not recruitingPhase 4

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Key facts

Who runs it
GlaxoSmithKline
Where
South Korea5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
50 people enrolled
Started
10 Nov 2023
Expected to end
8 Feb 2027
Type of study
Interventional
Treatments tested
  • rMenB+OMV NZ
Record updated
6 April 2026

Who can take part

Age
2 months to 5 months
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Participant's parent(s)/Legally acceptable representative(s) [LAR(s)], who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., return for follow-up visits)
  • Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure
  • Healthy participants as established by medical history and clinical examination before entering the study
  • Born full term (i.e., after a gestation period of ≥37 weeks)

Who cannot take part

  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant Therapy:
  • Use of any investigational or non-registered product (drug, vaccine or medical device) since birth, or their planned use during the study period
  • Previous vaccination with any group B meningococcal vaccine at any time prior to informed consent
  • Administration of long acting (defined as administered once per week or less frequently) immunosuppressants, including monoclonal antibodies (e.g., infliximab) since birth and/or planned use at any time during the study period
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) since birth and/or planned use of long-acting immune-modifying treatments at any time during the study period. For corticosteroids, this will mean prednisone equivalent 0.5 mg/kg/day. Inhaled and topical steroids are allowed
  • Administration of immunoglobulins and/or any blood products or plasma derivatives since birth and/or planned use at any time during the study period; Prior/Concurrent Clinical Study Experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device); Other Exclusion Criteria
  • Progressive, unstable or uncontrolled clinical conditions
  • Any contraindications to group B meningococcal vaccine, including but not limited to: history of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention
  • Medical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Any neuroinflammatory condition (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), any congenital neurological condition, encephalopathies, seizures (including all subtypes such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures)
  • Congenital or peripartum disorders resulting in a chronic illness (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders)
  • Other serious chronic illness
  • Hypersensitivity to latex
  • Abnormal function of the immune system resulting from clinical conditions, or administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth or autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes)
  • Known exposure from birth to an individual with laboratory confirmed N. meningitidis infection
  • Child in care
  • Any immediate dependents, family, or household member of study personnel

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republic of Korea according to a 2-dose primary schedule and 1 booster dose.

The group in the trial

  • rMenB+OMV NZ GroupTreatment being tested

    Participants received rMenB+OMV NZ on Day 1, Day 61, and any day between Day 241- Day 391.

    Treatment: rMenB+OMV NZ

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea
Record updated
6 April 2026